INTEGRATED BIOPHARMA INC (INBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 06-30. Amounts in USD.

Revenue Quarterly

0 6M 12M 18M Q4 '21: 17.1M Q1 '22: 12.8M Q2 '22: 14.6M Q3 '22: 15.6M Q4 '22: 13.3M Q1 '23: 12.3M Q2 '23: 12.3M Q3 '23: 13.1M Q4 '23: 13M Q1 '24: 12.9M Q2 '24: 11.5M Q3 '24: 13.1M Q4 '24: 12.7M Q1 '25: 13.6M Q2 '25: 12.6M Q3 '25: 13.9M Q4 '25: 14.2M Q1 '26: 12.7M Q2 '26: 11.3M Q3 '26: 10.1M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit Quarterly

-800K 0 800K 1.6M 2.4M Q4 '21: 2.3M Q1 '22: 1.4M Q2 '22: 1.8M Q3 '22: 2M Q4 '22: 1.4M Q1 '23: 997K Q2 '23: 1.1M Q3 '23: 1M Q4 '23: 986K Q1 '24: 832K Q2 '24: 520K Q3 '24: 1.2M Q4 '24: 1.3M Q1 '25: 1.4M Q2 '25: 1.2M Q3 '25: 1.6M Q4 '25: 1.5M Q1 '26: 1M Q2 '26: 29K Q3 '26: -276K Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Income Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q4 '21: 1.3M Q1 '22: 585K Q2 '22: 730K Q3 '22: 992K Q4 '22: 438K Q1 '23: 30K Q2 '23: -33K Q3 '23: 44K Q4 '23: 79K Q1 '24: -54K Q2 '24: -452K Q3 '24: 355K Q4 '24: 402K Q1 '25: 490K Q2 '25: 202K Q3 '25: 739K Q4 '25: 589K Q1 '26: 163K Q2 '26: -914K Q3 '26: -1.1M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income Quarterly

-2M 0 2M 4M 6M Q3 '21: 1.2M Q4 '21: 4.5M Q1 '22: 516K Q2 '22: 1M Q3 '22: 797K Q4 '22: 1.5M Q1 '23: -35K Q2 '23: -55K Q3 '23: 16K Q4 '23: 40K Q1 '24: -59K Q2 '24: -382K Q3 '24: 285K Q4 '24: 268K Q1 '25: 259K Q2 '25: 116K Q3 '25: 611K Q1 '26: 123K Q2 '26: -762K Q3 '26: -837K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q3 '26

Cost of Revenue Quarterly

0 6M 12M 18M Q4 '21: 14.8M Q1 '22: 11.3M Q2 '22: 12.8M Q3 '22: 13.7M Q4 '22: 11.9M Q1 '23: 11.3M Q2 '23: 11.2M Q3 '23: 12.1M Q4 '23: 12M Q1 '24: 12.1M Q2 '24: 11M Q3 '24: 11.9M Q4 '24: 11.5M Q1 '25: 12.2M Q2 '25: 11.4M Q3 '25: 12.4M Q4 '25: 12.7M Q1 '26: 11.7M Q2 '26: 11.3M Q3 '26: 10.4M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow Quarterly

-2M -1M 0 1M 2M 3M Q4 '21: 712K Q1 '22: 2.1M Q2 '22: -1.4M Q3 '22: 675K Q4 '22: 2.7M Q1 '23: 992K Q2 '23: -44K Q3 '23: 1.5M Q4 '23: -1.2M Q1 '24: 1.3M Q2 '24: -1.8M Q3 '24: 1.6M Q4 '24: -186K Q1 '25: 657K Q2 '25: 201K Q3 '25: 616K Q4 '25: 591K Q1 '26: 1.3M Q2 '26: 617K Q3 '26: 517K Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow Quarterly

-2M -1M 0 1M 2M 3M Q4 '21: 567K Q1 '22: 2M Q2 '22: -1.6M Q3 '22: 532K Q4 '22: 2.7M Q1 '23: 942K Q2 '23: -76K Q3 '23: 1.5M Q4 '23: -1.2M Q1 '24: 1.3M Q2 '24: -1.9M Q3 '24: 1.3M Q4 '24: -332K Q1 '25: 601K Q2 '25: 172K Q3 '25: 500K Q4 '25: 581K Q1 '26: 1.1M Q2 '26: 593K Q3 '26: 517K Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '20: 30.6M Q3 '20: 30.9M Q1 '21: 31.8M Q2 '21: 32.1M Q3 '21: 32.9M Q1 '22: 32.6M Q2 '22: 32.4M Q3 '22: 32.4M Q1 '23: 29.9M Q2 '23: 29.9M Q3 '23: 31.5M Q1 '24: 30M Q2 '24: 30.1M Q3 '24: 30.7M Q1 '25: 30.6M Q2 '25: 31.3M Q3 '25: 31.5M Q1 '26: 31.4M Q2 '26: 31.1M Q3 '26: 31.1M Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.09 0.00 0.09 0.18 0.27 Q4 '20: 0.13 Q1 '21: 0.15 Q2 '21: 0.16 Q3 '21: 0.17 Q4 '21: 0.25 Q1 '22: 0.24 Q2 '22: 0.23 Q3 '22: 0.22 Q4 '22: 0.13 Q1 '23: 0.11 Q2 '24: -0.01 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.01 Q2 '25: 0.03 Q3 '25: 0.04 Q4 '25: 0.04 Q1 '26: 0.03 Q2 '26: -0.01 Q3 '26: -0.06 Q1 '21 Q4 '21 Q3 '22 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.